Trials / Sponsors / Oblato, Inc.
Oblato, Inc.
Industry · 5 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Active Not Recruiting | Study of Safety and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma High-grade Glioma, Oligodendroglioma, Astrocytoma | Phase 1 | 2023-04-17 |
| Withdrawn | Investigation of Oral OKN-007 in Recurrent High-grade Glioma Participants Glioblastoma, Astrocytoma, Oligodendroglioma | Phase 1 / Phase 2 | 2022-08-01 |
| Completed | Open-label Study Investigating of OKN-007 Combined With Temozolomide in Patients With Recurrent Glioblastoma Recurrent Malignant Glioma, Brain Glioblastoma | Phase 2 | 2020-06-12 |
| Unknown | Clinical Trial of IV OKN-007 in a Pilot Cohort of Human Recurrent Malignant Glioma Patients Recurrent Malignant Glioma | Phase 1 | 2012-12-01 |
| No Longer Available | Expanded Access to OKN-007 for Patients With Diffuse Midline Glioma, H3 K27-altered Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma | — | — |